3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
210
Active not recruiting
166
Recruiting
143
Terminated
71
Unknown
68
Withdrawn
44
Not yet recruiting
18
Suspended
3
Enrolling by invitation
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Thoracic
1
Conditions
Small Cell Lung Carcinoma
1
Neoplasms
1
Interventions
Cisplatin
9
Standard of Care
6
Educational Status
6
Nivolumab
5
Interviews as Topic
5
Carboplatin
5
Radiotherapy
4
Paclitaxel
4
Oxaliplatin
4
Dexamethasone
4
pembrolizumab
3
camrelizumab
3
Practice Guidelines as Topic
3
Patient Navigation
3
Methods
3
Magnetic Resonance Spectroscopy
3
Magnetic Resonance Imaging
3
Lenalidomide
3
Fluorouracil
3
Fluorodeoxyglucose F18
3
Exercise
3
Early Intervention, Educational
3
Drug Therapy
3
Cytarabine
3
130-nm albumin-bound paclitaxel
3
venetoclax
2
toripalimab
2
tislelizumab
2
sacituzumab govitecan
2
lenvatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Enrolling by invitation
×
Interventional
×
durvalumab
×
Clear all
NCT05303532
2026-05-19
ROSY-D
AstraZeneca
Phase 3
Enrolling by invitation
214 enrolled
NCT06419179
2025-05-20
GUIDANCE
University of Cologne
Phase 2
Enrolling by invitation
29 enrolled